Results for tag: "Growth Hormone Deficiency Drug"

The Growth Hormone Deficiency Drug market is a segment of the Endocrine and Metabolic Disorders Drugs market. Growth hormone deficiency (GHD) is a condition in which the body does not produce enough growth hormone, which is essential for normal growth and development. Treatment for GHD involves the use of recombinant human growth hormone (rhGH) drugs, which are administered via injection. These drugs are used to stimulate growth in children with GHD, as well as to treat adults with GHD who have decreased muscle mass, increased body fat, and decreased bone density. The Growth Hormone Deficiency Drug market is highly competitive, with a number of major players offering a range of products. These include Eli Lilly, Novo Nordisk, Pfizer, Merck, and Sanofi. Other companies in the market include Ipsen, Ferring Pharmaceuticals, and Teva Pharmaceuticals. Show Less Read more